Thymoquinone induces cell proliferation inhibition and apoptosis in acute myeloid leukemia cells: role of apoptosis-related WT1 and BCL2 genes

Acute myeloid leukemia (AML) is an aggressive and heterogeneous disease characterized by an abnormal proliferation and impaired differentiation of the myeloid precursor cells. The outcome for most AML patients remains poor with high relapse rates and chemotherapy remains the first line treatment for AML. The Wilms tumor wt1 and the anti-apoptotic BCL2 genes are upregulated in AML and are known to be involved in apoptosis inhibition. In the present study we evaluated the molecular mechanisms underlie the anti-proliferative and pro-apoptotic activities exerted by thymoquinone (TQ), the major biologically active compound of the black seed oil on acute myeloid leukemia (AML) cell line-HL60. Cell proliferation was determined by WST-1 assay and apoptosis rate was assessed by flow cytometry using annexin-V/7AAD staining. The expression of target genes was analyzed by real-time RT–PCR analysis. TQ significantly reduced HL60 cell viability and induced apoptosis in a dose and time-dependent manner. In order to decipher the molecular mechanisms underlie the anti-cancer activities induced by TQ in AML cells, we investigated its effect on the expression of WT1 and BCL2 genes. TQ significantly decreased the expression of WT1 and BCL2 genes in a dose and time-dependent manner. In summary, these findings suggest that TQ induces cell proliferation inhibition and apoptosis in acute myeloid leukemia cells most likely through targeting the apoptosis-related WT1 and BCL2 genes and also suggest that TQ could be a promising strategy for AML therapy.

[1]  M. Alhosin,et al.  Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms , 2019, Epigenetics insights.

[2]  S. Fujiwara,et al.  Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse , 2018, Clinical lymphoma, myeloma & leukemia.

[3]  Y. Mély,et al.  Thymoquinone challenges UHRF1 to commit auto-ubiquitination: a key event for apoptosis induction in cancer cells , 2018, Oncotarget.

[4]  Bin Zhou,et al.  A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. , 2018, Experimental hematology.

[5]  Hai-ying Li,et al.  WT1 protein is cleaved by caspase-3 in apoptotic leukemic cells , 2018, Leukemia & lymphoma.

[6]  Chandragouda R. Patil,et al.  Therapeutic Potential and Pharmaceutical Development of Thymoquinone: A Multitargeted Molecule of Natural Origin , 2017, Front. Pharmacol..

[7]  M. Zauderer,et al.  Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1 , 2017, Oncotarget.

[8]  O. Haus,et al.  Heterogeneity of human WT1 gene. , 2017, Postepy higieny i medycyny doswiadczalnej.

[9]  Gheyath K Nasrallah,et al.  Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa , 2017, Critical reviews in food science and nutrition.

[10]  Shenming Wang,et al.  The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis , 2016, Oncotarget.

[11]  Zhishu Huang,et al.  Blocking the binding of WT1 to bcl-2 promoter by G-quadruplex ligand SYUIQ-FM05 , 2016, Biochemistry and biophysics reports.

[12]  A. Ishisaki,et al.  Expression of Wilms' tumor 1 (WT1) in ameloblastomas. , 2016, Journal of oral science.

[13]  T. Sharif,et al.  Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts , 2012, Investigational New Drugs.

[14]  T. Sharif,et al.  Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. , 2010, Biochemical pharmacology.

[15]  R. Verhaak,et al.  Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia. , 2010, Cancer treatment and research.

[16]  Alun D. Hughes,et al.  The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression , 2008, Oncogene.

[17]  Hartmut Döhner,et al.  Acute myeloid leukaemia , 2006, The Lancet.

[18]  L. Bergmann,et al.  Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds , 2006, Leukemia & lymphoma.

[19]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[20]  Sandip K. Mishra,et al.  Par-4 Transcriptionally Regulates Bcl-2 through a WT1-binding Site on the bcl-2 Promoter* , 2003, Journal of Biological Chemistry.

[21]  H. Ackermann,et al.  The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia , 2002, Leukemia.

[22]  C. Y. Wang,et al.  WT1 modulates apoptosis by transcriptionally upregulating the bcl‐2 proto‐oncogene , 1999, The EMBO journal.

[23]  J. Zhang,et al.  The AML1/ETO fusion protein activates transcription of BCL-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Ganser,et al.  Expression of CD7 and CD15 on Leukemic Blasts Are Prognostic Parameters in Patients with Acute Myelocytic Leukemia — Irrelevance of CD34 , 1996 .

[25]  U. Maurer,et al.  The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  D. Haber,et al.  The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. , 1995, Genes & development.

[27]  F. Keith,et al.  Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. , 1995, Leukemia.

[28]  S. Sacchi,et al.  Bcl-2 oncoprotein expression in acute myeloid leukemia. , 1995, Haematologica.

[29]  J. Brieger,et al.  The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. , 1994, Leukemia.

[30]  S. Proctor,et al.  The relationship between bcl‐2 expression and response to chemotherapy in acute leukaemia , 1994, British journal of haematology.

[31]  G. Saunders,et al.  Expression of the Wilms' tumor gene (WT1) in human leukemias. , 1992, Leukemia.